Stay updated on Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Added a new trial site: Tainan, Taiwan, 704, and removed the Tainan City, Taiwan, 704 listing; a government funding status notice was also deleted.
    Difference
    0.2%
    Check dated 2025-11-13T17:08:27.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    No substantive changes to the core study content were detected; observed differences are limited to layout or metadata changes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-30T11:32:08.000Z thumbnail image
  4. Check
    44 days ago
    Change Detected
    Summary
    Page updated to Revision: v3.2.0 from Revision: v3.0.2; indicates a new release version with no other substantive content changes.
    Difference
    0.0%
    Check dated 2025-10-01T05:35:37.000Z thumbnail image
  5. Check
    51 days ago
    Change Detected
    Summary
    - The page has removed key drug-safety topics (MedlinePlus Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), signaling a shift away from detailed drug-safety content.
    Difference
    0.3%
    Check dated 2025-09-24T01:06:29.000Z thumbnail image
  6. Check
    59 days ago
    Change Detected
    Summary
    - Added: Revision: v3.0.2. - Removed: Revision: v3.0.1 and a 'Back to Top' element. Overall, this is a small update to versioning metadata and a minor navigation change.
    Difference
    0.1%
    Check dated 2025-09-16T19:54:44.000Z thumbnail image
  7. Check
    66 days ago
    Change Detected
    Summary
    The page now includes the full MK-7684A-002 (KEYVIBE-002) trial details, including design, treatment arms (Pembrolizumab/Vibostolimab coformulation with/without Docetaxel vs placebo plus Docetaxel), outcomes, eligibility, enrollment, and completion status, plus a global list of trial sites, sponsor information, results posting dates, IPD sharing plans, and protocol links. This update significantly expands core content with proper nouns and logistical details, while deletions are limited to a version reference, indicating a major information addition rather than removal.
    Difference
    100%
    Check dated 2025-09-09T15:24:08.000Z thumbnail image

Stay in the know with updates to Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Vibostolimab Combo in NSCLC Clinical Trial page.